GRI Bio, Inc. (NASDAQ: GRI), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has received a Notice of Allowance from the United Arab Emirates Patent Office (UAE) for UAE Patent No. P6000687/2017, titled
“Prevention and Treatment of Inflammatory Conditions.”
The release this morning from the La Jolla, Calif.-based company says the allowed claims cover novel type 2 diverse NKT cell agonists and related methods and compositions for the prevention and treatment of inflammatory conditions, further expanding GRI Bio’s intellectual property protection for its proprietary immunomodulatory platform.
These claims support therapeutic approaches targeting immune pathways implicated in inflammatory, fibrotic and autoimmune diseases and complement the Company’s existing patent portfolio. This allowance further reinforces the Company’s disciplined approach to building a global intellectual property portfolio designed to support long-term exclusivity and strategic optionality.
The UAE represents a strategically significant and rapidly expanding healthcare market, serving as a gateway to the broader Middle East and North Africa (MENA) region. By securing patent protection in this region, GRI Bio strengthens its global intellectual property position for its dNKT cell agonist program and enhances its ability to support future regional partnerships, licensing opportunities and long-term commercialization strategies.
GRI shares collected 17 cents, or 7.6%, to $2.47.
Related Stories
